Is Marksans Pharma overvalued or undervalued?

Oct 12 2025 08:09 AM IST
share
Share Via
As of October 10, 2025, Marksans Pharma is considered overvalued with a PE ratio of 23.52 and a year-to-date return of -38.65%, contrasting sharply with the Sensex's positive performance.
As of 10 October 2025, Marksans Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently deemed overvalued based on its key ratios, including a PE ratio of 23.52, an EV to EBITDA of 15.66, and a PEG ratio of 4.80. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.96, while Cipla, considered attractive, has a PE ratio of 23.39.

Given these metrics, Marksans Pharma appears overvalued in the current market context. The company's recent stock performance has outpaced the Sensex over the past week and month, but its year-to-date return of -38.65% starkly contrasts with the Sensex's positive 5.58%, reinforcing concerns about its current valuation.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News